{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:35:00Z","timestamp":1788449700847,"version":"build-2803163510"},"reference-count":27,"publisher":"CSIRO Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":926,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We set out to estimate healthcare costs of diabetes complications in the year of first occurrence and the second year, and to quantify the incremental costs of diabetes versus non-diabetes related to each complication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cohort study, people with diabetes (n = 45 378) and their age\/sex propensity score matched controls (n = 90 756) were identified from a linked dataset in Tasmania, Australia between 2004 and 2017. Direct costs (including hospital, emergency room visits and pathology costs) were calculated from the healthcare system perspective and expressed in 2020 Australian dollars. The average-per-patient costs and the incremental costs in people with diabetes were calculated for each complication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First-year costs when the complications occurred were: dialysis $78 152 (95% CI 71 095, 85 858), lower extremity amputations $63 575 (58 290, 68 688), kidney transplant $48 487 (33 862, 68 283), non-fatal myocardial infarction $30 827 (29 558, 32 197), foot ulcer\/gangrene $29 803 (27 183, 32 675), ischaemic heart disease $29 160 (26 962, 31 457), non-fatal stroke $27 782 (26 285, 29 354), heart failure $27 379 (25 968, 28 966), kidney failure $24 904 (19 799, 32 557), angina pectoris $18 430 (17 147, 19 791), neuropathy $15 637 (14 265, 17 108), nephropathy $15 133 (12 285, 18 595), retinopathy $14 775 (11 798, 19 199), transient ischaemic attack $13 905 (12 529, 15 536), vitreous hemorrhage $13 405 (10 241, 17 321), and blindness\/low vision $12 941 (8164, 19 080). The second-year costs ranged from 16% (ischaemic heart disease) to 74% (dialysis) of first-year costs. Complication costs were 109\u2013275% higher than in people without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Diabetes complications are costly, and the costs are higher in people with diabetes than without diabetes. Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/ah22180","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:38:35Z","timestamp":1668447515000},"page":"667-678","source":"Crossref","is-referenced-by-count":9,"title":["Costs of major complications in people with and without diabetes in Tasmania, Australia"],"prefix":"10.1071","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2339-2628","authenticated-orcid":true,"given":"Ngan T. T.","family":"Dinh","sequence":"first","affiliation":[{"name":"AHealth Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia."},{"name":"BThai Nguyen University of Medicine and Pharmacy, Thai Nguyen University, Thai Nguyen, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"de Graaff","sequence":"additional","affiliation":[{"name":"AHealth Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"AHealth Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Jose","sequence":"additional","affiliation":[{"name":"CSchool of Medicine, University of Tasmania, Tas., Australia."},{"name":"DAustralia and New Zealand Dialysis and Transplant Registry (ANZDATA), SA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burgess","family":"John","sequence":"additional","affiliation":[{"name":"CSchool of Medicine, University of Tasmania, Tas., Australia."},{"name":"EDepartment of Endocrinology, Royal Hobart Hospital, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Saunder","sequence":"additional","affiliation":[{"name":"CSchool of Medicine, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kitsos","sequence":"additional","affiliation":[{"name":"CSchool of Medicine, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Wiggins","sequence":"additional","affiliation":[{"name":"FTasmanian Data Linkage Unit, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Palmer","sequence":"additional","affiliation":[{"name":"AHealth Economics Research Group, Menzies Institute for Medical Research, University of Tasmania, Tas., Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"issue":"6","key":"2025121501105134900_R1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1753-6405.2009.00450.x","article-title":"Projecting the burden of diabetes in Australia \u2013 what is the size of the matter?","volume":"33","author":"Magliano","year":"2009","journal-title":"Aust N Z J Public Health"},{"key":"2025121501105134900_R2"},{"issue":"1","key":"2025121501105134900_R3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030.","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2025121501105134900_R4","doi-asserted-by":"publisher","first-page":"6S9","DOI":"10.1016\/s1262-3636(03)72783-9","article-title":"The burden of type 2 diabetes: are we doing enough?","volume":"29","author":"Zimmet","year":"2003","journal-title":"Diabetes Metab"},{"issue":"11","key":"2025121501105134900_R5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","article-title":"The challenge of transparency and validation in health economic decision modelling: a view from Mount Hood.","volume":"37","author":"Kent","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2025121501105134900_R6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jval.2018.02.002","article-title":"Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge.","volume":"21","author":"Palmer","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"2025121501105134900_R7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","article-title":"Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.","volume":"16","author":"Palmer","year":"2013","journal-title":"Value Health"},{"issue":"6","key":"2025121501105134900_R8","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc07-9919","article-title":"Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.","volume":"30","author":"The","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"2025121501105134900_R9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1046\/j.1464-5491.2003.00972.x","article-title":"The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).","volume":"20","author":"Clarke","year":"2003","journal-title":"Diabet Med"},{"issue":"2","key":"2025121501105134900_R10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000236","article-title":"Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis.","volume":"7","author":"Clarke","year":"2010","journal-title":"PLoS Med"},{"issue":"10","key":"2025121501105134900_R11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1185\/030079905X65349","article-title":"Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.","volume":"21","author":"Ray","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2025121501105134900_R12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1524-4733.2007.00228.x","article-title":"Estimating the cost of complications of diabetes in Australia using administrative health-care data.","volume":"11","author":"Clarke","year":"2008","journal-title":"Value Health"},{"issue":"9","key":"2025121501105134900_R13","doi-asserted-by":"publisher","DOI":"10.2196\/20160","article-title":"Chronic kidney disease in Tasmania: Protocol for a data linkage study.","volume":"9","author":"Saunder","year":"2020","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"2025121501105134900_R14","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14817","article-title":"Incremental healthcare expenditure attributable to diabetes mellitus: a cost of illness study in Tasmania, Australia.","volume":"39","author":"Dinh","year":"2022","journal-title":"Diabet Med"},{"issue":"6","key":"2025121501105134900_R15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","article-title":"Diabetes Complications Severity Index (DCSI)\u2014Update and ICD-10 translation.","volume":"31","author":"Glasheen","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"7243","key":"2025121501105134900_R16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised trials be analysed?","volume":"320","author":"Thompson","year":"2000","journal-title":"BMJ"},{"issue":"23","key":"2025121501105134900_R17","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23&lt;3219::AID-SIM623&gt;3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: an application of the non-parametric bootstrap.","volume":"19","author":"Barber","year":"2000","journal-title":"Stat Med"},{"key":"2025121501105134900_R18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","article-title":"Cost-of-illness studies: a review of current methods.","volume":"24","author":"Akobundu","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"2025121501105134900_R19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00019053-200422030-00002","article-title":"Cost-of-Illness Studies in Diabetes Mellitus.","volume":"22","author":"Ettaro","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2025121501105134900_R20"},{"issue":"31","key":"2025121501105134900_R21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011602","article-title":"Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysis.","volume":"97","author":"Cheng","year":"2018","journal-title":"Medicine"},{"key":"2025121501105134900_R22"},{"issue":"16","key":"2025121501105134900_R23","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/archinte.159.16.1873","article-title":"The Progressive Cost of Complications in Type 2 Diabetes Mellitus.","volume":"159","author":"Brown","year":"1999","journal-title":"Arch Intern Med"},{"issue":"12","key":"2025121501105134900_R24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/dme.13806","article-title":"Health service utilization and related costs attributable to diabetes.","volume":"35","author":"O\u2019Neill","year":"2018","journal-title":"Diabet Med"},{"issue":"4","key":"2025121501105134900_R25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2337\/dc12-2625","article-title":"Economic Costs of Diabetes in the U.S. in 2012.","volume":"36","author":"American Diabetes Association.","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"2025121501105134900_R26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1499-2671(09)31007-2","article-title":"Prevalence, Total and Excess Costs of Diabetes and Related Complications in Ontario, Canada.","volume":"33","author":"Goeree","year":"2009","journal-title":"Can J Diabetes"},{"issue":"5","key":"2025121501105134900_R27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc17-1763","article-title":"Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany.","volume":"41","author":"K\u00e4hm","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Australian Health Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/46\/6\/667\/440727\/ah22180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/46\/6\/667\/440727\/ah22180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:11:01Z","timestamp":1765779061000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/ah\/article\/46\/6\/667\/71128\/Costs-of-major-complications-in-people-with-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12,8]]}},"URL":"https:\/\/doi.org\/10.1071\/ah22180","relation":{},"ISSN":["0156-5788","1449-8944"],"issn-type":[{"value":"0156-5788","type":"print"},{"value":"1449-8944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}